We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+9.34%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$612M
AUM Growth
+$115M
Cap. Flow
+$88.3M
Cap. Flow %
14.44%
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80

Top Buys

Rank Stock Value
1
TEO icon
Telecom Argentina
TEO
+$2.03M
2
MEOH icon
Methanex
MEOH
+$1.43M
3
EQM
EQM Midstream Partners, LP
EQM
+$1.32M
4
CGBD icon
Carlyle Secured Lending
CGBD
+$1.31M
5
GEO icon
The GEO Group
GEO
+$1.3M

Top Sells

Rank Stock Value
1
OXSQ icon
Oxford Square Capital
OXSQ
+$2.73M
2
MPLX icon
MPLX
MPLX
+$1.51M
3
MDCO
Medicines Co
MDCO
+$982K
4
GAIN icon
Gladstone Investment Corp
GAIN
+$857K
5
CELG
Celgene Corp
CELG
+$712K

Sector Composition

Rank Sector Weight
1 Financials 20.46%
2 Real Estate 16.88%
3 Energy 14.34%
4 Healthcare 10.85%
5 Materials 9.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
251
DELISTED
bluebird bio
BLUE
$403K 0.07%
355
+189
+114% +$205K
RYTM icon
252
Rhythm Pharmaceuticals
RYTM
$7.31B
$401K 0.07%
17,450
+6,142
+54% +$136K
TVRD
253
Tvardi Therapeutics
TVRD
$23.5M
$401K 0.07%
691
+329
+91% +$231K
QURE icon
254
uniQure
QURE
$2.7B
$399K 0.07%
5,561
+2,085
+60% +$114K
ARVN icon
255
Arvinas
ARVN
$539M
$398K 0.07%
9,698
-2,506
-21% -$73.4K
ARNA
256
DELISTED
Arena Pharmaceuticals Inc
ARNA
$398K 0.07%
8,758
+4,174
+91% +$197K
DCPH
257
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$397K 0.06%
6,371
-5,422
-46% -$258K
ACHN
258
DELISTED
Achillion Pharmaceuticals
ACHN
$397K 0.06%
65,813
-24,741
-27% -$143K
BBIO icon
259
BridgeBio Pharma
BBIO
$16.7B
$396K 0.06%
+11,295
New +$313K
ALLO icon
260
Allogene Therapeutics
ALLO
$639M
$395K 0.06%
15,214
+5,662
+59% +$156K
RIGL icon
261
Rigel Pharmaceuticals
RIGL
$713M
$395K 0.06%
+18,474
New +$380K
KDMN
262
DELISTED
Kadmon Holdings, Inc.
KDMN
$395K 0.06%
+87,094
New +$319K
TCRT icon
263
Alaunos Therapeutics
TCRT
$4.52M
$394K 0.06%
557
+234
+72% +$161K
TCDA
264
DELISTED
Tricida, Inc. Common Stock
TCDA
$394K 0.06%
10,444
+3,090
+42% +$115K
ARWR icon
265
Arrowhead Research
ARWR
$12.3B
$393K 0.06%
6,196
-3,589
-37% -$178K
ASMB icon
266
Assembly Biosciences
ASMB
$518M
$393K 0.06%
1,600
+146
+10% +$26.9K
MGTX icon
267
MeiraGTx Holdings
MGTX
$1.16B
$392K 0.06%
19,596
+7,285
+59% +$125K
AMRS
268
DELISTED
Amyris Inc.
AMRS
$390K 0.06%
126,372
+62,090
+97% +$230K
TBIO
269
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$388K 0.06%
+47,685
New +$440K
RGNX icon
270
Regenxbio
RGNX
$661M
$387K 0.06%
9,436
+4,204
+80% +$166K
XBIT icon
271
XBiotech
XBIT
$69.2M
$387K 0.06%
+20,735
New +$267K
MDGL icon
272
Madrigal Pharmaceuticals
MDGL
$12.9B
$385K 0.06%
4,226
+1,626
+63% +$158K
CRSP icon
273
CRISPR Therapeutics
CRSP
$4.71B
$384K 0.06%
+6,306
New +$344K
KURA icon
274
Kura Oncology
KURA
$947M
$383K 0.06%
27,872
+14,306
+105% +$212K
DNLI icon
275
Denali Therapeutics
DNLI
$3.79B
$380K 0.06%
21,805
+8,311
+62% +$138K
9 10
11
12 13

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2019 Portfolio in Review

As of Q4 2019, Virtus ETF Advisers held 532 positions worth $612M, up 23% from $496M the previous quarter. Its ten largest holdings account for 9% of the portfolio.

Virtus ETF Advisers deployed $88.3M of net new capital in Q4 2019, opening 97 new positions and adding to 238 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.

By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 24% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Oxford Square Capital, an estimated $2.73M trimmed.

  • Virtus ETF Advisers's largest Q4 2019 buy was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.
  • Virtus ETF Advisers added most to Telecom Argentina in Q4 2019, an estimated $2.03M increase.
  • Virtus ETF Advisers's biggest Q4 2019 reduction was Oxford Square Capital, cutting an estimated $2.73M.
  • Virtus ETF Advisers fully exited Medicines Co in Q4 2019, selling an estimated $982K.
  • Virtus ETF Advisers's ten largest holdings make up 9% of its $612M portfolio in Q4 2019.
  • Virtus ETF Advisers opened 97 new positions and closed 80 in Q4 2019.
  • Virtus ETF Advisers's portfolio value rose 23% quarter-over-quarter to $612M.

Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.